RU2008148325A - Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы - Google Patents
Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы Download PDFInfo
- Publication number
- RU2008148325A RU2008148325A RU2008148325/04A RU2008148325A RU2008148325A RU 2008148325 A RU2008148325 A RU 2008148325A RU 2008148325/04 A RU2008148325/04 A RU 2008148325/04A RU 2008148325 A RU2008148325 A RU 2008148325A RU 2008148325 A RU2008148325 A RU 2008148325A
- Authority
- RU
- Russia
- Prior art keywords
- polymorph
- dementia
- treatment
- ray
- powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
1. Кристаллический полиморф А (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, показывающий порошковую рентгенограмму с характеристическими пиками, выраженными в градусах (2-θ°): приблизительно 7,6 и 15,2 и 19,7. ! 2. Кристаллический полиморф В (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, показывающий порошковую рентгенограмму с характеристическими пиками, выраженными в градусах (2-θ°): приблизительно 8,0, 9,6 и 16,1. ! 3. Смесь полиморфов, содержащая полиморфы А по п.1 и B по п.2 в соотношениях 5:95-95:5. ! 4. Полиморф (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, где полиморф отделяют перекристаллизацией из этанола, метанола, изопропилового спирта, ацетона, этилацетата и/или ацетонитрила. ! 5. Кристаллический полиморф А, имеющий порошковую рентгенограмму, по существу, такую же, что показана в таблице 1. ! 6. Кристаллический полиморф В, имеющий порошковую рентгенограмму, по существу, такую же, что показана в таблице 2. ! 7. Полиоморф по любому одному из пп.1-6 для применения в терапии. ! 8. Применение полиморфа по любому одному из пп.1-6 в приготовлении лекарственного средства для лечения расстройств центральной нервной системы. ! 9. Способ лечения расстройств центральной нервной системы, включающий введение млекопитающему, нуждающемуся в таком лечении, терапевтически эффективного количества полиморфа по любому одному из пп.1-6. ! 10. Способ по п.9, где расстройство выбирают из группы, включающей возрастное нарушение памяти, умеренные когнитивные нарушения, предстарческое слабоумие (раннее начало болезни Альцгеймера), старческое слабоумие (слабоумие Альцгей
Claims (14)
1. Кристаллический полиморф А (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, показывающий порошковую рентгенограмму с характеристическими пиками, выраженными в градусах (2-θ°): приблизительно 7,6 и 15,2 и 19,7.
2. Кристаллический полиморф В (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, показывающий порошковую рентгенограмму с характеристическими пиками, выраженными в градусах (2-θ°): приблизительно 8,0, 9,6 и 16,1.
3. Смесь полиморфов, содержащая полиморфы А по п.1 и B по п.2 в соотношениях 5:95-95:5.
4. Полиморф (2S)-(4E)-N-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина п-гидроксибензоата, где полиморф отделяют перекристаллизацией из этанола, метанола, изопропилового спирта, ацетона, этилацетата и/или ацетонитрила.
5. Кристаллический полиморф А, имеющий порошковую рентгенограмму, по существу, такую же, что показана в таблице 1.
6. Кристаллический полиморф В, имеющий порошковую рентгенограмму, по существу, такую же, что показана в таблице 2.
7. Полиоморф по любому одному из пп.1-6 для применения в терапии.
8. Применение полиморфа по любому одному из пп.1-6 в приготовлении лекарственного средства для лечения расстройств центральной нервной системы.
9. Способ лечения расстройств центральной нервной системы, включающий введение млекопитающему, нуждающемуся в таком лечении, терапевтически эффективного количества полиморфа по любому одному из пп.1-6.
10. Способ по п.9, где расстройство выбирают из группы, включающей возрастное нарушение памяти, умеренные когнитивные нарушения, предстарческое слабоумие (раннее начало болезни Альцгеймера), старческое слабоумие (слабоумие Альцгеймеровского типа), деменцию с тельцами Леви, сосудистую деменцию, болезнь Альцгеймера, удар, комплекс СПИД-деменции, синдром дефицита внимания, синдром дефицита внимания с гиперактивностью, дислексию, шизофрению, шизофреноподобное расстройство и шизоаффективное расстройство.
11. Способ по п.9, где расстройство выбирают из группы, включающей лечение от легкого до среднего слабоумия Альцгеймеровского типа, синдрома дефицита внимания, умеренного когнитивного нарушения и возрастного нарушения памяти.
12. Фармацевтическая композиция, содержащая в качестве активного компонента терапевтически эффективное количество полиморфа по любому одному из пп.1-6 вместе с одним или более фармацевтически пригодными разбавителями, наполнителями и/или инертными носителями.
13. Фармацевтическая композиция по п.12, предназначенная для лечения расстройств центральной нервной системы.
14. Агент для лечения расстройств центральной нервной системы, который содержит в качестве активного компонента полиморф по любому одному из пп.1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74682106P | 2006-05-09 | 2006-05-09 | |
| US60/746,821 | 2006-05-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008148325A true RU2008148325A (ru) | 2010-06-20 |
| RU2440984C2 RU2440984C2 (ru) | 2012-01-27 |
Family
ID=38441430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008148325/04A RU2440984C2 (ru) | 2006-05-09 | 2007-05-08 | Полиморфные формы (2s)-(4е)-n-метил-5-[3-(5-изопропоксипиридин)ил]- 4-пентен-2-амина для лечения расстройств центральной нервной системы |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8461344B2 (ru) |
| EP (2) | EP2418201B1 (ru) |
| JP (1) | JP4477097B2 (ru) |
| KR (1) | KR20090005369A (ru) |
| CN (1) | CN101472893A (ru) |
| AR (1) | AR060786A1 (ru) |
| AU (1) | AU2007249485B2 (ru) |
| BR (1) | BRPI0709781A2 (ru) |
| CA (1) | CA2649961A1 (ru) |
| DK (1) | DK2418201T3 (ru) |
| EC (1) | ECSP088876A (ru) |
| ES (1) | ES2460919T3 (ru) |
| HR (1) | HRP20140385T1 (ru) |
| IL (1) | IL194833A0 (ru) |
| MX (1) | MX2008013982A (ru) |
| MY (1) | MY144132A (ru) |
| NO (1) | NO20084567L (ru) |
| NZ (1) | NZ597177A (ru) |
| PL (1) | PL2418201T3 (ru) |
| PT (1) | PT2418201E (ru) |
| RS (1) | RS53286B (ru) |
| RU (1) | RU2440984C2 (ru) |
| SA (1) | SA07280230B1 (ru) |
| SI (1) | SI2418201T1 (ru) |
| TW (1) | TWI389889B (ru) |
| UA (1) | UA96447C2 (ru) |
| UY (1) | UY30330A1 (ru) |
| WO (1) | WO2007134034A1 (ru) |
| ZA (1) | ZA200809284B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| EP2021325A2 (en) * | 2006-05-09 | 2009-02-11 | AstraZeneca AB | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| EP2112923A1 (en) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| CN101772343A (zh) * | 2007-07-31 | 2010-07-07 | 塔格赛普有限公司 | (2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药 |
| CN102065845A (zh) * | 2008-06-11 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物 |
| WO2010080757A2 (en) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| FR2959107B1 (fr) | 2010-04-23 | 2015-03-27 | Oreal | Unite d'application d'un produit cosmetique |
| US8703802B2 (en) * | 2010-05-20 | 2014-04-22 | Targacept, Inc. | Process for the preparation of aryl substituted olefinic amines |
| WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
| KR101579904B1 (ko) | 2014-09-05 | 2016-01-05 | 동신대학교산학협력단 | 마스카라 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192946A (en) | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
| DE3148651A1 (de) | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
| US4582823A (en) | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| ATE118216T1 (de) | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
| US5187166A (en) | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| WO1992012122A1 (en) | 1990-12-27 | 1992-07-23 | Abbott Laboratories | N-protected aminoalkylaldehydes |
| DE69213559T2 (de) | 1991-05-30 | 1997-02-27 | Mitsui Toatsu Chemicals | Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| IT1274018B (it) | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| DE69523155T2 (de) | 1994-06-14 | 2002-02-07 | Pfizer Inc., New York | Benzimidazolonderivate mit zentraler dopaminerger aktivität |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| EP1997806A1 (en) | 1996-04-23 | 2008-12-03 | Targacept, Inc. | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| ES2172882T3 (es) | 1997-05-08 | 2002-10-01 | Pfizer Prod Inc | Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos. |
| EP1027336B1 (en) | 1997-10-27 | 2004-10-06 | Neurosearch A/S | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| EP1086082B9 (en) | 1998-06-16 | 2005-03-02 | Targacept, Inc. | Arylsubstituted olefinic amines and their use as cholinergic receptors agonists |
| US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6337351B1 (en) | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| WO2000075110A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| EP1274433A1 (en) | 2000-04-13 | 2003-01-15 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| US6432954B1 (en) | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6743812B1 (en) | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CN1610547A (zh) | 2001-03-29 | 2005-04-27 | 伊莱利利公司 | 用作5－ht6受体拮抗剂的n－(2－芳乙基)苄胺 |
| GB2381750A (en) | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| BR0214929A (pt) | 2001-12-14 | 2006-05-30 | Targacept Inc | métodos e composições para o tratamento de distúrbios do sistema nervoso central |
| EP1575495A4 (en) | 2002-03-27 | 2009-12-02 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2549638A1 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| WO2006015299A2 (en) | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| JP4148199B2 (ja) | 2004-07-30 | 2008-09-10 | 松下電工株式会社 | 電気かみそり |
| US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| EP2021325A2 (en) | 2006-05-09 | 2009-02-11 | AstraZeneca AB | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| WO2007146319A2 (en) | 2006-06-13 | 2007-12-21 | Symphony Medical, Inc. | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
| WO2008034041A2 (en) | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| EP2112923A1 (en) | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
-
2007
- 2007-04-27 TW TW096115162A patent/TWI389889B/zh not_active IP Right Cessation
- 2007-05-07 UY UY30330A patent/UY30330A1/es not_active Application Discontinuation
- 2007-05-07 AR ARP070101972A patent/AR060786A1/es not_active Application Discontinuation
- 2007-05-08 EP EP11167528.6A patent/EP2418201B1/en active Active
- 2007-05-08 KR KR1020087027218A patent/KR20090005369A/ko active IP Right Grant
- 2007-05-08 RS RS20140212A patent/RS53286B/en unknown
- 2007-05-08 NZ NZ597177A patent/NZ597177A/xx not_active IP Right Cessation
- 2007-05-08 CA CA002649961A patent/CA2649961A1/en not_active Abandoned
- 2007-05-08 AU AU2007249485A patent/AU2007249485B2/en not_active Ceased
- 2007-05-08 US US11/745,682 patent/US8461344B2/en not_active Expired - Fee Related
- 2007-05-08 MY MYPI20084443A patent/MY144132A/en unknown
- 2007-05-08 SA SA07280230A patent/SA07280230B1/ar unknown
- 2007-05-08 DK DK11167528.6T patent/DK2418201T3/da active
- 2007-05-08 SI SI200731433T patent/SI2418201T1/sl unknown
- 2007-05-08 PT PT111675286T patent/PT2418201E/pt unknown
- 2007-05-08 RU RU2008148325/04A patent/RU2440984C2/ru not_active IP Right Cessation
- 2007-05-08 BR BRPI0709781-6A patent/BRPI0709781A2/pt not_active IP Right Cessation
- 2007-05-08 WO PCT/US2007/068446 patent/WO2007134034A1/en active Application Filing
- 2007-05-08 MX MX2008013982A patent/MX2008013982A/es active IP Right Grant
- 2007-05-08 JP JP2009503340A patent/JP4477097B2/ja not_active Expired - Fee Related
- 2007-05-08 PL PL11167528T patent/PL2418201T3/pl unknown
- 2007-05-08 EP EP07783431A patent/EP2021326A1/en not_active Withdrawn
- 2007-05-08 CN CNA2007800168072A patent/CN101472893A/zh active Pending
- 2007-05-08 ES ES11167528.6T patent/ES2460919T3/es active Active
- 2007-08-05 UA UAA200814135A patent/UA96447C2/ru unknown
-
2008
- 2008-10-22 IL IL194833A patent/IL194833A0/en unknown
- 2008-10-29 ZA ZA200809284A patent/ZA200809284B/xx unknown
- 2008-10-30 NO NO20084567A patent/NO20084567L/no not_active Application Discontinuation
- 2008-11-07 EC EC2008008876A patent/ECSP088876A/es unknown
-
2009
- 2009-10-29 US US12/608,450 patent/US20100048643A1/en not_active Abandoned
-
2013
- 2013-05-14 US US13/893,408 patent/US20130310425A1/en not_active Abandoned
-
2014
- 2014-04-28 HR HRP20140385TT patent/HRP20140385T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008148325A (ru) | Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы | |
| CN107567454B (zh) | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 | |
| HRP20110570T1 (hr) | Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora | |
| JPH10509150A (ja) | 酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ | |
| TW201412738A (zh) | 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚 | |
| AU2017201916B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| KR20220131520A (ko) | 아릴시클로헥실아민 유도체 및 정신장애 치료에서의 이의 용도 | |
| CN101031572A (zh) | (r/s)利福霉素衍生物，它们的制备和药物组合物 | |
| EP2938341A1 (en) | Heterocyclic compounds and methods of use thereof | |
| JP7198820B2 (ja) | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| WO2014134776A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| JP2015510513A (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| JP2007223916A (ja) | 抗菌剤 | |
| US20210198218A1 (en) | Compounds for therapeutic use | |
| TW202106680A (zh) | Glyt1抑制劑之固體形式 | |
| WO2021123372A1 (en) | Novel compounds and their use | |
| CN111662294A (zh) | 一类具有降解Btk活性的化合物 | |
| US9987244B2 (en) | Methods of treating ototoxicity | |
| KR20140105598A (ko) | [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도 | |
| HU199440B (en) | Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds | |
| JP7201688B2 (ja) | 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| CN109999033B (zh) | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 | |
| AU2017321416B2 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| EP4180428A1 (en) | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | |
| EA038333B1 (ru) | Антибактериальные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150509 |